FDA panels to consider Tysabri to treat Crohn's disease

05/29/2007 | Forbes

Two Food and Drug Administration panels are scheduled to review the drug Tysabri in July as a possible treatment for Crohn's disease. Studies indicate the drug, approved to treat multiple sclerosis, is effective in preventing inflammatory immune cells from penetrating intestinal walls.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT